Camberwell, Australia
AdAlta Ltd, founded in 2007, is an Australian-based company at the forefront of biotechnology and healthcare innovation. The company aims to revolutionize cancer treatment by leading in the realm of cellular immunotherapies for solid cancers, with a particular focus on therapies originating from Asia, notably China, and bringing them to western regulated markets.
Through its subsidiary, AdCella, AdAlta Ltd in-licenses top-tier assets, facilitates cost-effective manufacturing, and produces clinical data in Australia. This strategy benefits their Asian partners, offering a route to western markets while sharing profits.
Their proprietary i-body technology showcases assets like AD-214, targeting lung and kidney fibrosis, and poised for Phase 2 trials. Another asset, WD-34, stands as a groundbreaking solution against parasites such as malaria.
The latest funding round in 2026 injected $2.50M into AdAlta Ltd, positioning it strategically for further growth and innovations. Such advancements make AdAlta Ltd a compelling prospect for investors eyeing transformative cancer therapies and fibrotic disease treatments.
